Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis-Reference-Cited by-同舟云学术

Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis

Published:2007-02-16 Issue:5 Volume:13 Page:683-685
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Alanoglu G.¹,Kilbas S.²,Arslan C.³,Senol A.³,Kutluhan S.²

Affiliation:

1. Department of Internal Medicine, Division of Hematology, School of Medicine, Suleyman Demirel University, 32100 Isparta, Turkey,

2. Department of Neurology, School of Medicine, Suleyman Demirel University, Isparta, Turkey

3. Department of Internal Medicine, School of Medicine, Suleyman Demirel University, Isparta, Turkey

Abstract

A 31-year-old patient with multiple sclerosis (MS), treated with interferon beta-1b (IFNB-1b) for two years, presented with fatigue and dizziness. Coombs' positive autoimmune hemolytic anemia (AIHA) was found. Other potential etiologies of AIHA were ruled out. An association with IFNB-1b was highly suspected. Interferon therapy was discontinued and prednisone therapy instituted. There was resolution of the hemolytic anemia, and prednisone therapy was tapered gradually. To the best of our knowledge, there is no reported case of the development of AIHA associated with IFNB-1b use in MS patients. We conclude that if an unexplained drop in hematocrit occurs with a MS patient receiving IFNB-1b, autoimmune mediated hemolysis should also be considered. Multiple Sclerosis 2007; 13: 683-685. http://msj.sagepub.com

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458506071333

Reference10 articles.

1. Autoimmune events during interferon beta-1b treatment for multiple sclerosis

2. Multiple Sclerosis

3. Autoantibodies in Multiple Sclerosis Patients Before and During IFN-β1b Treatment: Are They Correlated with the Occurrence of Autoimmune Diseases?

4. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

5. Immune-Mediated Complications during Interferon Therapy in Hematological Patients

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series;Frontiers in Neurology;2024-06-18

2. Severe Autoimmune intravascular hemolytic anemia in patients receiving Alemtuzumab for Multiple sclerosis;Blood Advances;2022-11-14

3. Interferon-α2b induced anemia in severe coronavirus disease 2019 patients: a single centered, retrospective study;Immunopharmacology and Immunotoxicology;2021-10-26

4. Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis;Multiple Sclerosis Journal;2018-01-23

5. Anemia and dysregulation of iron metabolism in multiple sclerosis;Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2018